BioAt­la rakes in $72.5M Se­ries D, ad­vanc­ing re­search for pH-de­tect­ing can­cer treat­ments

A lit­tle over a year af­ter agree­ing to a world­wide col­lab­o­ra­tion with hefty Chi­nese biotech BeiGene worth up to $270 mil­lion, BioAt­la is ready for an­oth­er haul.

The San Diego-based biotech pulled in a $72.5 mil­lion haul for their Se­ries D fi­nanc­ing, which the com­pa­ny an­nounced Wednes­day. Funds will go to­ward their four main clin­i­cal pro­grams de­vel­op­ing can­cer treat­ments, two of which are cur­rent­ly in Phase II, BioAt­la pres­i­dent and for­mer Cel­gene COO Scott Smith said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER